Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19
Copyright © 2023. Published by Elsevier Inc..
There is scant information on the clinical progression, end-of-life decisions, and cause of death of patients with cancer diagnosed with COVID-19. Therefore, we conducted a case series of patients admitted to a comprehensive cancer center who did not survive their hospitalization. To determine the cause of death, 3 board-certified intensivists reviewed the electronic medical records. Concordance regarding cause of death was calculated. Discrepancies were resolved through a joint case-by-case review and discussion among the 3 reviewers. During the study period, 551 patients with cancer and COVID-19 were admitted to a dedicated specialty unit; among them, 61 (11.6%) were nonsurvivors. Among nonsurvivors, 31 (51%) patients had hematologic cancers, and 29 (48%) had undergone cancer-directed chemotherapy within 3 months before admission. The median time to death was 15 days (95% confidence interval [CI], 11.8 to 18.2). There were no differences in time to death by cancer category or cancer treatment intent. The majority of decedents (84%) had full code status at admission; however, 53 (87%) had do-not-resuscitate orders at the time of death. Most deaths were deemed to be COVID-19 related (88.5%). The concordance between the reviewers for the cause of death was 78.7%. In contrast to the belief that COVID-19 decedents die because of their comorbidities, in our study only 1 of every 10 patients died of cancer-related causes. Full-scale interventions were offered to all patients irrespective of oncologic treatment intent. However, most decedents in this population preferred care with nonresuscitative measures rather than full support at the end of life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Mayo Clinic proceedings - 98(2023), 3 vom: 03. März, Seite 451-457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reddy, Dereddi Raja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 12.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mayocp.2022.12.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353746495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353746495 | ||
| 003 | DE-627 | ||
| 005 | 20231226060726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mayocp.2022.12.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353746495 | ||
| 035 | |a (NLM)36868753 | ||
| 035 | |a (PII)S0025-6196(22)00702-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reddy, Dereddi Raja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a There is scant information on the clinical progression, end-of-life decisions, and cause of death of patients with cancer diagnosed with COVID-19. Therefore, we conducted a case series of patients admitted to a comprehensive cancer center who did not survive their hospitalization. To determine the cause of death, 3 board-certified intensivists reviewed the electronic medical records. Concordance regarding cause of death was calculated. Discrepancies were resolved through a joint case-by-case review and discussion among the 3 reviewers. During the study period, 551 patients with cancer and COVID-19 were admitted to a dedicated specialty unit; among them, 61 (11.6%) were nonsurvivors. Among nonsurvivors, 31 (51%) patients had hematologic cancers, and 29 (48%) had undergone cancer-directed chemotherapy within 3 months before admission. The median time to death was 15 days (95% confidence interval [CI], 11.8 to 18.2). There were no differences in time to death by cancer category or cancer treatment intent. The majority of decedents (84%) had full code status at admission; however, 53 (87%) had do-not-resuscitate orders at the time of death. Most deaths were deemed to be COVID-19 related (88.5%). The concordance between the reviewers for the cause of death was 78.7%. In contrast to the belief that COVID-19 decedents die because of their comorbidities, in our study only 1 of every 10 patients died of cancer-related causes. Full-scale interventions were offered to all patients irrespective of oncologic treatment intent. However, most decedents in this population preferred care with nonresuscitative measures rather than full support at the end of life | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Cuenca, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Botdorf, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Muthu, Mayoora |e verfasserin |4 aut | |
| 700 | 1 | |a Hanmandlu, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Wegner, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Crommett, John |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Rathi, Nisha |e verfasserin |4 aut | |
| 700 | 1 | |a Sajith, Bilja |e verfasserin |4 aut | |
| 700 | 1 | |a Knafl, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Hussein A |e verfasserin |4 aut | |
| 700 | 1 | |a Woodman, Scott E |e verfasserin |4 aut | |
| 700 | 1 | |a Nates, Joseph L |e verfasserin |4 aut | |
| 700 | 0 | |a D3CODE Team Collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Aaroe, Ashley |e investigator |4 oth | |
| 700 | 1 | |a Aloia, Thomas A |e investigator |4 oth | |
| 700 | 1 | |a Andrews, Lee |c 2nd |e investigator |4 oth | |
| 700 | 1 | |a Badami, Kiran K |e investigator |4 oth | |
| 700 | 1 | |a Baganz, Janna A |e investigator |4 oth | |
| 700 | 1 | |a Bajwa, Pratibha |e investigator |4 oth | |
| 700 | 1 | |a Baker, Lori R |e investigator |4 oth | |
| 700 | 1 | |a Barbosa, Gregory R |e investigator |4 oth | |
| 700 | 1 | |a Beird, Hannah C |e investigator |4 oth | |
| 700 | 1 | |a Bourgeois, Matt |e investigator |4 oth | |
| 700 | 1 | |a Brock, Kristy |e investigator |4 oth | |
| 700 | 1 | |a Burton, Elizabeth M |e investigator |4 oth | |
| 700 | 1 | |a Cata, Juan |e investigator |4 oth | |
| 700 | 1 | |a Chung, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Cutherell, Michael |e investigator |4 oth | |
| 700 | 1 | |a Cuenca, John A |e investigator |4 oth | |
| 700 | 1 | |a Cyr, Pierre B |e investigator |4 oth | |
| 700 | 1 | |a Dabaja, Bouthaina |e investigator |4 oth | |
| 700 | 1 | |a Dagher, Hiba |e investigator |4 oth | |
| 700 | 1 | |a Daniels, Kevin M |e investigator |4 oth | |
| 700 | 1 | |a Domask, Mary |e investigator |4 oth | |
| 700 | 1 | |a Draetta, Giulio |e investigator |4 oth | |
| 700 | 1 | |a Fisher, Sarah |e investigator |4 oth | |
| 700 | 1 | |a French, Katy Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Futreal, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Gaeta, Maria |e investigator |4 oth | |
| 700 | 1 | |a Gibbons, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Godoy, Myrna |e investigator |4 oth | |
| 700 | 1 | |a Goldstein, Drew |e investigator |4 oth | |
| 700 | 1 | |a Gunther, Jillian |e investigator |4 oth | |
| 700 | 1 | |a Hernandez, Cristhiam |e investigator |4 oth | |
| 700 | 1 | |a Hutcheson, Kate |e investigator |4 oth | |
| 700 | 1 | |a Jaffray, David |e investigator |4 oth | |
| 700 | 1 | |a Jin, Jeff |e investigator |4 oth | |
| 700 | 1 | |a John, Teny Matthew |e investigator |4 oth | |
| 700 | 1 | |a Kell, Trey |e investigator |4 oth | |
| 700 | 1 | |a Knafl, Mark |e investigator |4 oth | |
| 700 | 1 | |a Kothari, Anai |e investigator |4 oth | |
| 700 | 1 | |a Kwan, Rayson C |e investigator |4 oth | |
| 700 | 1 | |a Lee, J Jack |e investigator |4 oth | |
| 700 | 1 | |a Liao, Yue |e investigator |4 oth | |
| 700 | 1 | |a Litton, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Liu, Alex |e investigator |4 oth | |
| 700 | 1 | |a McEnery, Kevin W |e investigator |4 oth | |
| 700 | 1 | |a McGuire, Mary |e investigator |4 oth | |
| 700 | 1 | |a Musunuru, Tego |e investigator |4 oth | |
| 700 | 1 | |a Muthu, Mayoora |e investigator |4 oth | |
| 700 | 1 | |a Nates, Joseph L |e investigator |4 oth | |
| 700 | 1 | |a Owen, Craig S |e investigator |4 oth | |
| 700 | 1 | |a Padmakumar, Priyadharshini |e investigator |4 oth | |
| 700 | 1 | |a Page, Melody |e investigator |4 oth | |
| 700 | 1 | |a Palaskas, Nicholas |e investigator |4 oth | |
| 700 | 1 | |a Patel, Jay J |e investigator |4 oth | |
| 700 | 1 | |a Prabhakaran, Sabitha |e investigator |4 oth | |
| 700 | 1 | |a Bajwa, Pratibha |e investigator |4 oth | |
| 700 | 1 | |a Ravi, Vinod |e investigator |4 oth | |
| 700 | 1 | |a Russell, Ludivine |e investigator |4 oth | |
| 700 | 1 | |a Sajith, Bilja |e investigator |4 oth | |
| 700 | 1 | |a Scheet, Paul A |e investigator |4 oth | |
| 700 | 1 | |a Schmidt, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Shaw, Kenna R |e investigator |4 oth | |
| 700 | 1 | |a Shete, Sanjay |e investigator |4 oth | |
| 700 | 1 | |a Shoenthal, Daniel P |e investigator |4 oth | |
| 700 | 1 | |a Stoltenberg, Lessley J |e investigator |4 oth | |
| 700 | 1 | |a Subbiah, Ishwaria |e investigator |4 oth | |
| 700 | 1 | |a Suitor, Chuck |e investigator |4 oth | |
| 700 | 1 | |a Tawbi, Hussein |e investigator |4 oth | |
| 700 | 1 | |a Thompson, Phillip |e investigator |4 oth | |
| 700 | 1 | |a Turin, Anastasia |e investigator |4 oth | |
| 700 | 1 | |a Unni, Samir |e investigator |4 oth | |
| 700 | 1 | |a Vicknamparampil, Benju |e investigator |4 oth | |
| 700 | 1 | |a Weber, Max C |e investigator |4 oth | |
| 700 | 1 | |a Weinstein, John |e investigator |4 oth | |
| 700 | 1 | |a Williams, Zoe |e investigator |4 oth | |
| 700 | 1 | |a Woodman, Scott E |e investigator |4 oth | |
| 700 | 1 | |a Wozny, Mark C |e investigator |4 oth | |
| 700 | 1 | |a Wu, Carol |e investigator |4 oth | |
| 700 | 1 | |a Wu, Jia |e investigator |4 oth | |
| 700 | 1 | |a Yao, James C |e investigator |4 oth | |
| 700 | 1 | |a Young, Chingyi |e investigator |4 oth | |
| 700 | 1 | |a Yu, Emily |e investigator |4 oth | |
| 700 | 1 | |a Zatorski, Steven |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Mayo Clinic proceedings |d 1964 |g 98(2023), 3 vom: 03. März, Seite 451-457 |w (DE-627)NLM000074527 |x 1942-5546 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2023 |g number:3 |g day:03 |g month:03 |g pages:451-457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mayocp.2022.12.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2023 |e 3 |b 03 |c 03 |h 451-457 | ||